45 Kazia Theraputics Limited Annual Report 2023 Chairman and CEO’s Letter Key Milestones Introduction to Kazia’s CEO Pipeline Review Environment, Society and Governance Financial Reports STATEMENT OF CHANGES IN EQUITY CONTINUED For the year ended 30 June 2023 Contributed equity Other contributed equity Foreign currency translation reserve Share based payments reserve Accumulated losses Total equity Consolidated $ $ $ $ $ $ Balance at 1 July 2022 84,480,249 - (852,038) 3,263,703 (68,617,391) 18,274,523 Loss after income tax benefit for the year - - - - (20,465,180) (20,465,180) Other comprehensive income for the year, net of tax - - 110,248 - - 110,248 Total comprehensive income for the year - - 110,248 - (20,465,180) (20,354,932) Transactions with owners in their capacity as owners: Shares issued (note 20) 13,372,747 - - - - 13,372,747 Share issue costs (note 20) (400,750) - - - - (400,750) Share based payments (note 35) - - - 1,159,125 - 1,159,125 Expired options - - - (162) - (162) Balance at 30 June 2023 97,452,246 - (741,790) 4,422,666 (89,082,571) 12,050,551 The above statement of changes in equity should be read in conjunction with the accompanying notes
RkJQdWJsaXNoZXIy MjE2NDg3